- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | ASIT Biotech: ASIT biotech Mode of Action Study of gp-ASIT+ for Grass Pollen Allergy Published in The Journal ... | 2 | GlobeNewswire (USA) | ||
| Do | ASIT biotech mode of action study of gp-ASIT+ for grass pollen allergy published in The Journal of Allergy and Clinical Immunology (JACI)1 | 173 | Business Wire | Data show how gp-ASIT+, administered in a pre-seasonal 3-week treatment, is able to rapidly modulate the cellular response and induce production of blocking antibodies. This effect led to a significant... ► Artikel lesen | |
| 07.10. | ASIT biotech Receives GMP Certification | 1 | Contract Pharma | ||
| Börsennews zur ASIT BIOTECH Aktie und weiteren Hot Stocks erhalten | |||||
| 07.10. | ASIT Biotech: ASIT biotech Receives GMP Certification for its Manufacturing Site in Liège, Belgium | 2 | GlobeNewswire (USA) | ||
| 07.10. | ASIT biotech receives GMP certification for its manufacturing site in Liège, Belgium | 272 | Business Wire | Regulatory News:
ASIT biotech (BSE:ASIT) (Paris:ASIT) (ASIT BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough... ► Artikel lesen | |
| 03.10. | ASIT biotech: Information on the Total Number of Voting Rights and Shares | 205 | Business Wire | Regulatory News:
ASIT biotech (BSE:ASIT) (Paris:ASIT) (ASIT BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough... ► Artikel lesen | |
| 26.09. | ASIT Biotech: ASIT biotech Firmly on Course for Readout of Phase III Clinical Study in Grass Pollen Allergy | 2 | GlobeNewswire (USA) | ||
| 26.09. | ASIT biotech firmly on course for readout of Phase III clinical study in grass pollen allergy | 243 | Business Wire | The Company has passed the Last Patient Last Visit (LPLV) milestone in the pivotal gp-ASIT+ Phase III trial and remains on track to deliver primary efficacy results in December 2019. ASIT... ► Artikel lesen | |
| 19.09. | ASIT biotech - Building to a crescendo | 150 | Edison Investment Research | Having reported H119 financials, ASIT's main focus remains on the results of the second Phase III study of gp-ASIT+ for the prevention of grass pollen allergy. These are expected towards the end of... ► Artikel lesen | |
| 18.09. | ASIT biotech presents its 2019 half year results and provides further update on its clinical programs until end-2019 | 302 | Business Wire | Cash position of €2.5 million as of 30 June 2019, reinforced in July 2019 by the private placement of Convertible Notes for a total amount of 9.2 million out of which 5.0 million was paid immediately... ► Artikel lesen | |
| 10.09. | ASIT biotech Conference Calendar H2 2019 | 304 | Business Wire | Regulatory News:
ASIT biotech (BSE:ASIT) (Paris:ASIT) (ASIT BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough... ► Artikel lesen | |
| 05.09. | ASIT Biotech: Successful Pollen Season Confirms ASIT biotech On Track for Phase III Results of gp-ASIT+ in December ... | 3 | GlobeNewswire (USA) | ||
| 05.09. | Successful Pollen Season Confirms ASIT biotech on Track for Phase III Results of gp-ASIT+ in December 2019 | 244 | Business Wire | End of pollen season reached in all sites, allowing for last subject visits according to plan
Vaccine industry veteran Beatrice De Vos, MD, to join ASIT biotech as Chief Medical Officer
... ► Artikel lesen | |
| 01.08. | ASIT biotech: Information on the Total Number of Voting Rights and Shares | 43 | Business Wire | Regulatory News:
ASIT biotech (ASIT BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy... ► Artikel lesen | |
| 22.07. | ASIT Biotech: ASIT biotech Raises EUR 9.225 Million in a Private Placement of Convertible Notes | 3 | GlobeNewswire (USA) | ||
| 22.07. | ASIT biotech Raises EUR 9.225 Million in a Private Placement of Convertible Notes | 33 | Business Wire | Regulatory News:
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER... ► Artikel lesen | |
| 18.07. | ASIT biotech Announces the Launch of a Private Placement of Convertible Notes | 53 | Business Wire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT... ► Artikel lesen | |
| 04.07. | ASIT biotech: Information on the Total Number of Voting Rights and Shares | 504 | Business Wire | Regulatory News:
ASIT biotech (BSE:ASIT) (Paris:ASIT) (ASIT BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough... ► Artikel lesen | |
| 01.07. | ASIT biotech Continues Its Transformation From Research to Late Stage Clinical Development | 42 | Business Wire | Company shareholders approve all motions at Extraordinary General Meeting Firm expects to raise €9-12 M to finance focused development Jean-Paul Prieels confirmed as new member of Board... ► Artikel lesen | |
| 24.06. | Long-term investors look for stability, which India has: Asit Bhatia | 2 | Livemint |
Seite:
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MOLOGEN | 0,884 | -4,54 % | Mittagsbörse: DAX gibt nach - Daimler, Volkswagen, Aixtron, K+S, Mologen im Blick | Nachdem der DAX besonders in der zweiten Hälfte der letzten Handelswoche kräftig zulegen konnte, gibt er heute zum Handelsstart einen Teil dieser Gewinne wieder ab. Aktuell liegt der DAX 0,6 Prozent... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,740 | -1,10 % | Palatin Technologies: Kurspotenzial bis 6 USD! | Vancouver (www.aktiencheck.de) - Palatin Technologies-Aktienanalyse von Analyst John Newman von Canaccord Genuity: John Newman, Aktienanalyst von Canaccord Genuity, rät Investoren laut einer Aktienanalyse... ► Artikel lesen | |
| CO.DON | 2,630 | -0,38 % | CO.DON: Lizenz-Gespräche "auch um den nordamerikanischen Wirtschaftsraum" | Im Exklusiv-Interview mit der 4investors-Redaktion spricht CO.DON-Chef Ralf Jakobs unter anderem über die anstehenden Lizenzdeals und Kapitalmaßnahmen. Auch an anderer Stelle stehen Meilensteine an:... ► Artikel lesen | |
| HEAT BIOLOGICS | 0,340 | -1,88 % | HEAT BIOLOGICS, INC. - 8-K, Current Report | ||
| SIRONA BIOCHEM | 0,309 | -2,52 % | IRW-News: Sirona Biochem Corp.: Sirona Biochem: Feier zur Unterzeichnung der Vereinbarung mit Rodan + Fields auf der Konferenz Cosmetic 360 in Paris | IRW-PRESS: Sirona Biochem Corp.: Sirona Biochem: Feier zur
Unterzeichnung der Vereinbarung mit Rodan + Fields auf der Konferenz
Cosmetic 360 in Paris
Vancouver, British Columbia - 15. Oktober... ► Artikel lesen | |
| AETERNA ZENTARIS | 1,037 | +14,21 % | Aeterna Zentaris Inc (3): Aeterna Zentaris appoints Paulini CEO, replacing Ward | ||
| VALNEVA | 2,800 | -1,41 % | 21st Austria weekly - Wienerberger, Valneva (30/09/2019) | Wienerberger: Wienerberger, world's largest producer of bricks and a leading supplier of clay roof tiles, concrete pavers and pipe systems in Europe, has strengthened its market position in the attractive... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 5,780 | -0,52 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 10.10.2019 - 2 | FOLGENDE WERTPAPIERE WERDEN AM 10.10.2019 EX KAPITALMASSNAHME GEHANDELT. THE FOLLOWING SHARES ARE TRADED EX CAPITAL ADJUSTMENT ON 10.10.2019. INSTR EXCH ISIN INSTRUMENT NAME HBC2 XFRA US4042804066... ► Artikel lesen | |
| GERON | 1,350 | +0,48 % | Better Buy: Geron vs. Celgene | ||
| SANGUI BIOTECH | 0,016 | 0,00 % | DGAP-News: Sangui BioTech International Inc.:Umsätze von USD 88.001 im Geschäftsjahr 2019 (deutsch) | Sangui BioTech International Inc.:Umsätze von USD 88.001 im Geschäftsjahr 2019
DGAP-News: Sangui BioTech International Inc. / Schlagwort(e): Jahresergebnis
Sangui BioTech International Inc.:Umsätze... ► Artikel lesen | |
| GALAPAGOS NV | 140,05 | -4,53 % | Galapagos Holding S.A. -- Moody's withdraws Galapagos' ratings | ||
| PHARMING | 1,177 | +2,75 % | Pharming Responds to Press Speculation | Pharming categorically denies having had any involvement in the alleged abstraction of proprietary information by Dr Joseph Chiao from his former employer CSL
LEIDEN, Netherlands, Oct.... ► Artikel lesen | |
| CELLECTIS | 8,805 | -6,53 % | Cellectis: Monthly Information on Share Capital and Company Voting Rights | (Article 223-16 of General Regulation of the French financial markets authority)
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS):
Listing market: Euronext Growth
ISIN code:... ► Artikel lesen | |
| AMYRIS | 3,269 | +4,47 % | AMYRIS, INC. - 8-K, Current Report | ||
| COHERUS | 16,920 | +2,70 % | Coherus BioSciences, Inc.: Coherus BioSciences Announces New Employment Inducement Grants |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
